Wire · operational-macro
US FDA declines to approve Capricor's cell therapy for Duchenne muscular dystrophy; shares slump
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 November 2026 · Fusion42 review
The US FDA has declined to approve Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy due to serious data integrity issues in clinical trials, causing the company’s shares to drop sharply.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 12 Nov 2026 and 21 Nov 2026.
◆ ◆ The Wire takeaway
The FDA’s rejection shuts down the fastest route to market for muscle disease treatments that rely on this cell therapy approach. You need to rethink your clinical evidence strategy and funding runway if your venture is betting on this therapy’s success.
◆ Coverage
7 sources · first reported 12 Nov 2026 · latest 21 Nov 2026
◆ Related on Wire
◆ Topics